• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Research Updates: Do glucosamine-based chondroprotective agents affect fructosamine monitoring in diabetic dogs?

December 1, 2010

This study demonstrated that short-term administration of glucosamine-chondroitin sulfate does not significantly affect serum fructosamine concentrations in healthy dogs.

Glucosamine is a precursor of glycosaminoglycans, a major component of normal cartilage matrix. Supplementation with a combination of glucosamine and chondroitin sulfate ameliorates signs of osteoarthritis in dogs and people and is commonly prescribed to veterinary patients with suspected or confirmed degenerative joint disease. However, because glucosamine is composed of glucose and glutamine, administration of such chondroprotective agents could, in theory, increase serum glucose concentrations and thereby increase an animal's insulin requirements even further or, alternatively, could be contributing to pancreatic beta cell death by worsening hyperglycemia-associated glucose toxicity.

Getty Images/Image Source

Fructosamine, which is formed by the nonenzymatic glycosylation of albumin, is often measured when monitoring insulin therapy in diabetic dogs. Increases in serum fructosamine concentration in most cases are due to sustained hyperglycemia, so results above the reference range in a diabetic patient usually imply inadequate insulin dosing. The goal of this study was, therefore, to determine the impact of oral glucosamine-chondroitin sulfate supplementation on fructosamine concentrations in healthy dogs and, thereby, provide preliminary data on whether clinicians should consider the impact of this agent on monitoring protocols in diabetic patients.

Twelve healthy adult dogs were enrolled in this prospective, blinded, crossover study. Dogs fed a therapeutic diet designed to treat joint disease were excluded from enrollment because these diets may contain an undetermined amount of glucosamine. Six dogs (group 1) were randomly allocated to receive glucosamine-chondroitin sulfate once daily at the manufacturer's recommended dose for three weeks, and six dogs (group 2) were randomly allocated to receive a placebo (microcrystalline cellulose) once daily incorporated into an identical capsule for three weeks. Serum fructosamine concentrations were measured in all dogs before and at the end of the treatment period.

Advertisement

After completion of the first three-week study period, the glucosamine-chondroitin sulfate and placebo were discontinued in all dogs, and following a four-week washout period, group 1 dogs were then administered the placebo for three weeks, while group 2 dogs received the chondroprotective agent, again with measurement of serum fructosamine concentrations before and after treatment. Statistical analysis revealed that there was no difference in mean fructosamine concentrations before or after administration of glucosamine-chondroitin sulfate or placebo, and no significant difference was seen between fructosamine concentrations observed in dogs receiving the chondroprotective agent vs. the placebo.

COMMENTARY

This study demonstrated that short-term administration of glucosamine-chondroitin sulfate does not significantly affect serum fructosamine concentrations in healthy dogs. Although a previous study had determined that administration of a chondroprotective agent to healthy dogs for 30 days does not increase serum glucose concentration,1 direct confirmation that serum fructosamine concentrations were likewise unaffected was necessary because of the effects of this class of drugs on glucose homeostasis in different mammalian species.

For example, glucosamine induces insulin resistance in rats but not in healthy people or those with type 2 diabetes mellitus,2 likely because the conversion of glucose and glutamine to glucosamine is irreversible in humans and is, therefore, unlikely to result in hyperglycemia2 ; whether or not the same is true in dogs is unknown.

Because of this uncertainty, one could theorize, for example, that if glucosamine-derived serum glucose in dogs were to somehow be preferentially and rapidly bound to serum albumin, this would result in normal serum glucose but increased serum fructosamine concentrations. Therefore, any suggested redundancy of this study with previous investigations of glucose homeostasis in dogs administered chondroitin-based supplements is not justified.

Despite this justification for directly determining whether fructosamine concentrations are affected by short-term administration of glucosamine-chondroitin sulfate, two important limitations of this study prevent definitively stating that glucosamine-chondroitin sulfate supplements will have no effect on glucose homeostasis. First, the effect of this supplement on serum fructosamine concentrations was studied in healthy dogs rather than in dogs with diabetes mellitus. Several metabolic pathways (i.e. not just glucose homeostasis) are altered in patients with this disease, and, as such, glucosamine catabolism and biologic activity of any drug metabolites could in theory differ between these two populations. Second, chondroprotective agents are often administered for months to years rather than the 30-day period described in this study. Effects of glucosamine-chondroitin sulfate on glucose homeostasis may in theory be cumulative rather than immediate, so further studies that examine the type and importance of drug-associated effects following long-term administration are warranted.

Finally, although only hypothetical, chondroprotective agents such as glucosamine may have additional adverse effects that are unrelated to alterations in serum glucose concentration or homeostasis. This is a concern because glycosaminoglycans (such as heparin) are known substrates in or modulators of a number of unrelated metabolic processes. In fact, prolongation of several coagulation parameters two hours after parenteral administration of polysulfated glycosaminoglycans has been reported in dogs,3 although a later study failed to detect alterations in PT, APTT, or BMBT.1 Practitioners should keep in mind that this class of drugs has the potential for a wide range of adverse effects, particularly those agents classified as supplements, which may not have undergone rigorous toxicity studies.

The information in "Research Updates" was provided by Erika Meler, DVM, MS, and Barrak Pressler, DVM, PhD, DACVIM, Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907.

REFERENCES

1. Beale BS, Goring RL, Clemmons RM, et al. The effects of semi-synthetic polysulfated glycosaminoglycan on the hemostatic mechanism in the dog [abstr]. Vet Surg 1990;19:57.

2. McNamara PS, Barr SC, Erb HN. Hematologic, hemostatic, and biochemical effects in dogs receiving an oral chondroprotective agent for thirty days. Am J Vet Res 1996;57(9):1390-1394.

3. Scroggie DA, Albright A, Harris MD. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Arch Intern Med 2003;163(13):1587-1590.

Related Content:

OrthopedicsEndocrinology
Using in-clinic cortisol testing to detect endocrine diseases in dogs
Using in-clinic cortisol testing to detect endocrine diseases in dogs
Tools for addressing osteoarthritis pain
Tools for addressing osteoarthritis pain
Innovative ways for managing lumbosacral disease
Innovative ways for managing lumbosacral disease

Advertisement

Latest News

American Veterinary Medical Foundation welcomes new executive director

Details of new pet performance supplement line revealed

Veterinary scene Down Under: DEI advancements, plus title protection and more

Temple Grandin receives honorary degree from Kansas State University College of Veterinary Medicine

View More Latest News
Advertisement